Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 189-196

  Anderson, W F ^a   Luo, S ^a   Chatterjee, N ^a   Rosenberg, P S ^a   Matsuno, R K ^a   Goodman, M T ^b   Hernandez, B Y ^b   Reichman, M ^a   Dolled Filhart, M P ^c   O'Regan, R M ^d   Garcia Closas, M ^a   Perou, C M ^e   Jatoi, I ^f   Cartun, R W ^g   Sherman, M E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c HistoRx   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^g HARTFORD HOSPITAL   (United States)

Author keywords

Breast cancer incidence and survival; Estrogen receptor (ER); Human epidermal growth factor receptor 2 (HER2); Immunohistochemical stains; SEER; Tissue microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UNITED STATES;

AGE DISTRIBUTION; AGE OF ONSET; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; REPRODUCIBILITY OF RESULTS; SEER PROGRAM;

EID: 58049209741     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9918-3     Document Type: Article

References (30)

1. MT Goodman BY Hernandez S Hewitt CF Lynch TR Cote HF Frierson Jr 2005 Tissues from population-based cancer registries: a novel approach to increasing research potential Hum Pathol 36 7 812 820
2. SEER-13. Surveillance, Epidemiology, and End Results (SEER) Program ( http://seer.cancer.gov ) SEER*Stat Database: Incidence-SEER 13 Regs Limited-Use, Nov 2006 sub (1992-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission 2007
3. XR Yang ME Sherman DL Rimm J Lissowska LA Brinton B Peplonska 2007 Differences in risk factors for breast cancer molecular subtypes in a population-based study Cancer Epidemiol Biomarkers Prev 18 439 447
4. ME Sherman DL Rimm XR Yang N Chatterjee LA Brinton J Lissowska 2007 Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based study Int J Cancer 121 1079 1085
5. Rubin DB (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, New York
6. Fleiss JL (1981) The measurement of interrater agreement. In: Statistical methods for rates and proportions, 2nd edn. John Wiley & Sons, Inc, New York, pp 212-236
7. WF Anderson N Chatterjee WB Ershler OW Brawley 2002 Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database Breast Cancer Res Treat 76 1 27 36
8. Randles RH, Wolfe DA (1979) Introduction to the theory of non-parametric statistics. John Wiley & Sons, New York
9. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182
10. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 707 712
11. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145
12. H Yaziji LC Goldstein TS Barry R Werling H Hwang GK Ellis 2004 HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 16 1972 1977
13. M Bilous C Ades J Armes J Bishop R Brown B Cooke 2003 Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study Breast 12 2 92 98
14. HJ Burstein 2005 The distinctive nature of HER2-positive breast cancers N Engl J Med 353 16 1652 1654
15. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684
16. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672
17. R Zeillinger F Kury K Czerwenka E Kubista G Sliutz W Knogler 1989 HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer Oncogene 4 1 109 114
18. S Marsigliante A Muscella V Ciardo S Barker G Leo V Baker 1993 Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades Cancer Lett 75 3 195 206
19. E Tagliabue S Menard JF Robertson L Harris 1999 c-erbB-2 expression in primary breast cancer Int J Biol Markers 14 1 16 26
20. HJ Huang P Neven M Drijkoningen R Paridaens H Wildiers E Van Limbergen 2005 Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer Ann Oncol 16 11 1755 1761
21. CC Benz GK Scott JC Sarup RM Johnson D Tripathy E Coronado 1992 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 2 85 95
22. RJ Pietras J Arboleda DM Reese N Wongvipat MD Pegram L Ramos 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 12 2435 2446
23. DR Ciocca FE Gago MA Fanelli SK Calderwood 2006 Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications J Steroid Biochem Mol Biol 102 1-5 32 40
24. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2492 2502
25. B Kreike M van Kouwenhove H Horlings B Weigelt H Bartelink MJ Van de Vijver 2007 Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas Breast Cancer Res 9 5 R65
26. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752
27. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 8423
28. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 9 1721 1728
29. WF Anderson I Jatoi SS Devesa 2005 Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome Breast Cancer Res Treat 90 2 127 137
30. WF Anderson RM Pfeiffer GM Dores ME Sherman 2006 Comparison of age frequency distribution patterns for different histopathologic types of breast carcinoma Cancer Epidemiol Biomarkers Prev 15 10 1899 1905